Neurocrine Biosciences | NBIX - Cost Of Sales



Neurocrine Biosciences reported $11.3M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
AbbVie USD 4.35B 344M Jun/2025
Acadia Pharmaceuticals USD 20.73M 342K Jun/2025
Agios Pharmaceuticals USD 1.7M 617K Jun/2025
ALKERMES USD 49.46M 263K Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Amgen USD 3.01B 406M Jun/2025
Biogen USD 605M 24.3M Jun/2025
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Cytokinetics 112.55M 12.71M Jun/2025
Dynavax Technologies USD 14.04M 13.5M Jun/2025
Exelixis USD 19.47M 298K Jul/2025
Gilead Sciences USD 1.5B 39M Jun/2025
Halozyme Therapeutics USD 64.12M 15.72M Jun/2025
Incyte USD 78.77M 10.96M Jun/2025
Ionis Pharmaceuticals USD 4.15M 3.15M Jun/2025
Neurocrine Biosciences USD 11.3M 2.1M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
Prothena 40.52M 39.55M Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Repligen USD 91.22M 12.81M Jun/2025
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
Teva Pharmaceutical Industries USD 2.07B 97M Jun/2025
Ultragenyx Pharmaceutical USD 23M 5.66M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025